CJ-PURE (CJC-1295) by Meditech is a pharmaceutical-grade synthetic Growth Hormone Releasing Hormone (GHRH) analogue formulated as a lyophilized injectable peptide at 2 mg per vial. CJC-1295 is a modified tetrasubstituted peptide analogue of endogenous GHRH with an established research history in neuroendocrinological and peptide pharmacology literature, investigated for its capacity to stimulate sustained endogenous growth hormone secretion through pituitary GHRH receptor activation — representing a mechanistically distinct approach to growth hormone modulation relative to both exogenous somatropin and growth hormone secretagogue peptides such as GHRP-6.
 
✔ Key Research Insights
Studied for its role as a GHRH receptor agonist, with documented stimulation of pituitary somatotroph cells to release endogenous growth hormone in research subjects, producing a more sustained GH elevation profile relative to native GHRH in neuroendocrinological research
Investigated for its downstream effects on IGF-1 production following GH stimulation, with associated influences on lean mass parameters and tissue repair mechanisms documented in peptide pharmacology observations
Researched for its influence on metabolic parameters and body composition indices in clinical observations, mediated through sustained growth hormone secretagogue activity in documented subject populations
Examined for its effects on recovery markers, sleep architecture quality, and cellular regeneration parameters across peptide research literature
Documented for its extended plasma half-life relative to native GHRH, attributed to structural modifications including drug affinity complex technology in some formulations, associated with prolonged and stable GH stimulation in comparative peptide pharmacokinetic research
Manufactured by Meditech to pharmaceutical-grade purity and lyophilized peptide formulation standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: CJ-PURE
Molecule: CJC-1295
Concentration: 2 mg per vial
Appearance: Lyophilized white powder
Form: Injectable peptide requiring reconstitution prior to administration
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
CJC-1295 is a synthetic tetrasubstituted peptide analogue of growth hormone releasing hormone (GHRH), the endogenous hypothalamic peptide responsible for stimulating pituitary growth hormone secretion. In research subjects, CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, stimulating the pulsatile release of endogenous growth hormone into systemic circulation. Unlike native GHRH — which is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) enzymes in plasma, resulting in a very short half-life of only minutes — CJC-1295 incorporates structural modifications at four amino acid positions that confer significant resistance to enzymatic degradation, producing a markedly extended plasma half-life and correspondingly prolonged duration of pituitary GH stimulation documented in comparative peptide pharmacokinetic research. The sustained GH elevation produced by CJC-1295 administration subsequently stimulates hepatic IGF-1 production, with downstream effects on protein synthesis, cellular regeneration, and metabolic regulation documented across peptide pharmacology research literature. CJC-1295 is mechanistically distinct from growth hormone secretagogue peptides such as GHRP-6 in that it acts via the GHRH receptor rather than the ghrelin receptor, and the two classes are frequently examined in combination research protocols for their potentially additive effects on pituitary GH output. Reconstitution with bacteriostatic water is standard protocol prior to subcutaneous administration in documented research settings, with lyophilized storage ensuring peptide stability and bioactivity prior to use.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade purity and lyophilized peptide formulation standards
GHRH receptor agonist with a well-documented neuroendocrinological mechanism of action, stimulating sustained endogenous growth hormone secretion through a mechanistically distinct pathway relative to growth hormone secretagogue peptides
Extended plasma half-life relative to native GHRH documented in comparative peptide pharmacokinetic research, associated with prolonged and stable pituitary GH stimulation profiles
Widely referenced in neuroendocrinological and peptide pharmacology research under the CJC-1295 and GHRH analogue designations
Available in lyophilized vial format requiring reconstitution prior to subcutaneous administration per standard peptide research protocols